EWTX Stock Analysis: Buy, Sell, or Hold?
EWTX - Edgewise Therapeutics, Inc. Common Stock
$44.18
0.89 (2.06%)
â˛
5d:
+0.02%
30d:
+12.45%
90d:
+35.15%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Aug 20, 2026 at $43.29 · last confirmed Aug 21, 2026
Strength: 6.4/10
Get Alerted When EWTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: EWTX is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: EWTX is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: EWTX is currently trading at $44.18, which is considered slightly high relative to its 30-day fair value range of $39.42 to $44.30.
Technical Outlook: Technically, EWTX is in a strong uptrend. Immediate support is located at $41.98, while resistance sits at $46.59.
Market Sentiment: EWTX scores 39/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $51.69 (+17.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, EWTX is in a strong uptrend. Immediate support is located at $41.98, while resistance sits at $46.59.
Market Sentiment: EWTX scores 39/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $51.69 (+17.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$39.42 -
$44.30
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
39.5%
All Signals
- BEARISH: Weak technical setup (39/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($51.69)
- WARNING: Composite score 50/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$39.42 -
$44.30
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$41.98
Resistance Level
$46.59
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-24.33
Wall Street Target
$51.69
(+17.0%)
Share & Embed Analysis
Last updated: August 24, 2026 12:11 AM ET
Data refreshes hourly during market hours. Next update: 1:11 AM
Data refreshes hourly during market hours. Next update: 1:11 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EWTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Joanne M Donovan
SELL
28662 shares
2026-04-01
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals âĻ |
STRONG BUY
30 analysts |
$370 | 42 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 27 SELL |
|
VRTX
Vertex Pharmaceuticals IâĻ |
BUY
34 analysts |
$560 | 30 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$313 | 51 HOLD |
|
APLS
Apellis Pharmaceuticals âĻ |
BUY
22 analysts |
$41 | 50 HOLD |
